ANCROD IN RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

ANCROD 治疗快速进展性肾小球肾炎

• 批准号: 3884157
• 负责人: VICTOR E POLLAK
• 金额: --
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3884157
• 关键词: clinical trials; fibrinolytic agents; glomerulonephritis; human subject; human therapy evaluation; kidney disorder chemotherapy; kidney pharmacology; longitudinal human study; nephrosclerosis; prednisone

Two new patients studied. Long-term survival of 22 patients with lupus nephritis treated with ancrod was evaluated. The results, submitted for publication, showed good survival despite severity of disease. Particularly, they demonstrated a key role for alpha2-antiplasmin in predicting progression to sclerosis.

研究了两名新患者。 22例狼疮患者的长期生存 评价用Ancrod治疗的肾炎。 结果，提交给 发表，显示了良好的生存，尽管疾病的严重程度。 特别是，他们证明了α 2-抗纤溶酶在 预测硬化症的发展